Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Dystrophin pre-mRNA exon 50 is a critical exon within the pre-mRNA transcript of the DMD gene. Mutations or deletions affecting this exon often disrupt the reading frame, leading to Duchenne muscular dystrophy. Therapeutic strategies, such as exon skipping using antisense oligonucleotides, aim to restore the reading frame and produce a truncated but partially functional dystrophin protein.
Antisense oligonucleotides (AOs) induce exon skipping during pre-mRNA splicing, restoring the reading frame and allowing for the production of a truncated, but partially functional, dystrophin protein.
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Dystrophin pre-mRNA Exon 50 (DMD Exon 50).